Celltrion acquires approval of world’s first anticancer antibody biosimilar ‘Truxima’

Celltrion announced on the 22^nd that Truxima(generic name: rituximab), an antibody biosimilar for the treatment of hematologic malignancy and autoimmune disease, has acquired sales approval from the European Medicines Agency(EMA). The EMA has approved the treatment for all indications of reference rituximab which Celltrion filed for, such as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia ...